Blood Tests to Study Prostate Cancer Treatment Response
Collects blood samples from adults with prostate cancer to study markers in blood.
Plain-language title generated from the registry record
Registry title: Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients
Key facts
- Where
- Bellinzona, SwitzerlandSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older with prostate cancer (adenocarcinoma) who need treatment. Blood samples are collected to study markers that may predict how well the treatment works.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma at different stages, confirmed by tissue examination, for which treatment is indicated. Some groups ask for known CSPC or CRPC. One group is for men whose biopsy found no cancer.
- Earlier treatment
- Group 1: no previous radical surgery or radical radiotherapy, and no previous hormonal treatment. Group 2: no previous hormonal treatment for advanced disease. Some groups: no antibiotic treatment in the 2 months before joining.
Main reasons for not taking part
- Active infection that needs treatment
- Decrease of general condition
- Other severe illnesses at the same time
- Need for steroids at study entry and during the study
- A second tumor diagnosed in the previous 5 years
Read by machine on 12 November 2026.
Where in Switzerland
- Oncology Institute of Southern Switzerland (IOSI)Bellinzona, SwitzerlandContact: Pereira Mestre Ricardo, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Oncology Institute of Southern Switzerland
- Trial code
- NCT03408964
- Record updated
- 18 November 2025
- Original description
Participants to the study will be assigned to 7 cohorts according to the stage of disease and planned antitumor treatment at time of study entry.Read full original descriptionShow less
An Exploratory proof-of Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients, a Single Center Study
Participants to the study will be assigned to 7 cohorts according to the stage of disease and planned antitumor treatment at time of study entry.
In all patients, 12 ml of blood sample will be collected in EDTA tube for analysis of biological biomarkers in different time points.
Inclusion: General inclusion criteria (for entering all groups); Age ≥ 18 years; Histological diagnosis of prostate adenocarcinoma at different stages of disease (see Section 6.2) for which a treatment is indicated; Written Informed Consent; Inclusion criterion only for entering Group 0; Patients with a known diagnosis of CSPC or CRPC; Inclusion criterion only for entering Group 1a; Patients that underwent biopsies for a suspect of PC, but resulted negative for cancer.
Exclusion: Concomitant severe comorbities; Need of concomitant steroids at study entry and during the study; Diagnosis of second tumor in the previous 5 years; Exclusion criterion only for entering Group 0; No antibiotic treatments in the previous 2 months before enrollment; Previous radical surgery and / or radical radiotherapy; Previous hormonal treatments; No antibiotic treatments in the previous 2 months before enrollment (only in patients enrolling also for metagenomics and metabolomics); Previous hormonal treatments for advanced disease; Exclusion criterion only for entering Group 3; No antibiotic treatments in the previous 2 months before enrollment (only in patients enrolling also for metagenomics and metabolomics analyses); Active infection requiring treatment; Decrease of general condition; Difficult socioeconomic conditions making regular follow up unfeasible; General exclusion criteria (for entering all groups).